| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 11 | 2023 | 44 | 3.000 |
Why?
|
| Cerebellar Neoplasms | 10 | 2023 | 45 | 2.950 |
Why?
|
| Brain Neoplasms | 37 | 2023 | 848 | 2.770 |
Why?
|
| Glioma | 20 | 2023 | 321 | 2.580 |
Why?
|
| Brain Stem Neoplasms | 12 | 2022 | 21 | 2.390 |
Why?
|
| Astrocytoma | 17 | 2022 | 89 | 2.280 |
Why?
|
| Child | 60 | 2025 | 7618 | 1.160 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2023 | 1463 | 1.070 |
Why?
|
| Child, Preschool | 44 | 2022 | 3970 | 0.960 |
Why?
|
| Phacoemulsification | 6 | 2011 | 19 | 0.810 |
Why?
|
| Tomography, Optical Coherence | 4 | 2011 | 131 | 0.790 |
Why?
|
| Medicare Part C | 1 | 2022 | 7 | 0.760 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 31 | 0.750 |
Why?
|
| Cornea | 3 | 2011 | 55 | 0.740 |
Why?
|
| Humans | 120 | 2025 | 95802 | 0.730 |
Why?
|
| Viral Vaccines | 1 | 2022 | 48 | 0.720 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 171 | 0.720 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 11 | 0.710 |
Why?
|
| Plasma Exchange | 1 | 2021 | 28 | 0.710 |
Why?
|
| Stem Cell Transplantation | 4 | 2011 | 193 | 0.700 |
Why?
|
| Dacarbazine | 3 | 2016 | 101 | 0.680 |
Why?
|
| Indians, North American | 2 | 2013 | 48 | 0.670 |
Why?
|
| Fuchs' Endothelial Dystrophy | 2 | 2010 | 11 | 0.670 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 2 | 2010 | 18 | 0.660 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2025 | 99 | 0.660 |
Why?
|
| Vaccination | 2 | 2023 | 311 | 0.640 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2011 | 135 | 0.640 |
Why?
|
| Vena Cava Filters | 1 | 2021 | 90 | 0.630 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 228 | 0.610 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 111 | 0.600 |
Why?
|
| Cardiovascular Diseases | 4 | 2014 | 777 | 0.600 |
Why?
|
| Combined Modality Therapy | 14 | 2023 | 1739 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2025 | 2605 | 0.570 |
Why?
|
| Macular Edema | 3 | 2009 | 46 | 0.570 |
Why?
|
| Male | 71 | 2025 | 45686 | 0.560 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 257 | 0.560 |
Why?
|
| Adolescent | 40 | 2025 | 9873 | 0.560 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 235 | 0.560 |
Why?
|
| Chemoradiotherapy | 4 | 2017 | 327 | 0.550 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 2385 | 0.550 |
Why?
|
| Neoplasms | 9 | 2023 | 3242 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-myc | 6 | 2025 | 152 | 0.540 |
Why?
|
| Methionine | 1 | 2017 | 68 | 0.520 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2013 | 325 | 0.510 |
Why?
|
| Female | 68 | 2025 | 49872 | 0.490 |
Why?
|
| Lens Implantation, Intraocular | 7 | 2011 | 24 | 0.450 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2019 | 162 | 0.450 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 186 | 0.430 |
Why?
|
| Infant | 22 | 2022 | 3360 | 0.430 |
Why?
|
| Medicine, Traditional | 1 | 2013 | 8 | 0.400 |
Why?
|
| Glioblastoma | 3 | 2011 | 285 | 0.400 |
Why?
|
| Licensure | 1 | 2013 | 7 | 0.400 |
Why?
|
| Administration, Metronomic | 1 | 2013 | 2 | 0.400 |
Why?
|
| Mutation | 5 | 2019 | 4374 | 0.400 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 48 | 0.400 |
Why?
|
| Pons | 2 | 2011 | 26 | 0.390 |
Why?
|
| Oxides | 1 | 2013 | 44 | 0.390 |
Why?
|
| Arsenicals | 1 | 2013 | 49 | 0.380 |
Why?
|
| Endothelial Cells | 10 | 2014 | 477 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 517 | 0.370 |
Why?
|
| Leukocytes | 1 | 2013 | 213 | 0.360 |
Why?
|
| Hematopoiesis | 1 | 2013 | 182 | 0.360 |
Why?
|
| Cranial Irradiation | 4 | 2016 | 41 | 0.350 |
Why?
|
| Gliosarcoma | 1 | 2011 | 11 | 0.340 |
Why?
|
| Microvessels | 1 | 2011 | 69 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 307 | 0.330 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 404 | 0.330 |
Why?
|
| Aged | 22 | 2025 | 20848 | 0.330 |
Why?
|
| Retrospective Studies | 16 | 2022 | 10273 | 0.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 701 | 0.330 |
Why?
|
| Survival Rate | 11 | 2017 | 1971 | 0.320 |
Why?
|
| Bone Marrow | 2 | 2011 | 415 | 0.320 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2008 | 10 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2010 | 403 | 0.310 |
Why?
|
| Young Adult | 18 | 2020 | 7026 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2019 | 611 | 0.310 |
Why?
|
| Aqueous Humor | 1 | 2009 | 21 | 0.310 |
Why?
|
| Diabetic Retinopathy | 2 | 2009 | 82 | 0.310 |
Why?
|
| Treatment Outcome | 20 | 2025 | 9167 | 0.310 |
Why?
|
| Stem Cells | 6 | 2013 | 394 | 0.300 |
Why?
|
| Prognosis | 17 | 2022 | 3990 | 0.300 |
Why?
|
| Multiple Myeloma | 2 | 2011 | 353 | 0.300 |
Why?
|
| Supratentorial Neoplasms | 2 | 2008 | 10 | 0.300 |
Why?
|
| United States | 7 | 2022 | 7764 | 0.290 |
Why?
|
| Flow Cytometry | 8 | 2013 | 726 | 0.280 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 3904 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 942 | 0.270 |
Why?
|
| Middle Aged | 24 | 2025 | 28208 | 0.270 |
Why?
|
| Cytokines | 1 | 2011 | 871 | 0.260 |
Why?
|
| Lymphoma | 3 | 2010 | 253 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2011 | 2592 | 0.250 |
Why?
|
| Life Style | 1 | 2008 | 186 | 0.250 |
Why?
|
| Depressive Disorder | 1 | 2008 | 226 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2020 | 3639 | 0.250 |
Why?
|
| Social Environment | 1 | 2008 | 195 | 0.250 |
Why?
|
| Adult | 28 | 2025 | 28578 | 0.250 |
Why?
|
| Risk Factors | 10 | 2021 | 5961 | 0.240 |
Why?
|
| Bone Marrow Cells | 5 | 2011 | 270 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 644 | 0.240 |
Why?
|
| Radiotherapy Dosage | 6 | 2013 | 476 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 1166 | 0.230 |
Why?
|
| Pilot Projects | 2 | 2023 | 936 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 5 | 2014 | 354 | 0.230 |
Why?
|
| Brain | 6 | 2022 | 2480 | 0.220 |
Why?
|
| Transplantation, Autologous | 6 | 2022 | 361 | 0.220 |
Why?
|
| Rectal Neoplasms | 4 | 2007 | 134 | 0.210 |
Why?
|
| Platelet Count | 2 | 2021 | 91 | 0.210 |
Why?
|
| Biomarkers | 6 | 2023 | 1931 | 0.210 |
Why?
|
| Infratentorial Neoplasms | 3 | 2018 | 4 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2014 | 299 | 0.200 |
Why?
|
| Temporal Lobe | 2 | 2016 | 195 | 0.200 |
Why?
|
| Depression | 1 | 2008 | 560 | 0.200 |
Why?
|
| Oligodendroglioma | 2 | 2014 | 45 | 0.200 |
Why?
|
| Ipilimumab | 1 | 2023 | 63 | 0.200 |
Why?
|
| Rituximab | 2 | 2025 | 132 | 0.200 |
Why?
|
| Craniospinal Irradiation | 1 | 2022 | 1 | 0.200 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 437 | 0.190 |
Why?
|
| Disease Management | 2 | 2016 | 360 | 0.190 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2002 | 4 | 0.190 |
Why?
|
| Fluvoxamine | 1 | 2022 | 4 | 0.190 |
Why?
|
| Ivermectin | 1 | 2022 | 6 | 0.190 |
Why?
|
| Melanoma, Experimental | 2 | 2014 | 111 | 0.190 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.190 |
Why?
|
| Biomarkers, Tumor | 6 | 2013 | 1670 | 0.190 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2022 | 11 | 0.190 |
Why?
|
| Retina | 1 | 2004 | 219 | 0.190 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2002 | 4 | 0.190 |
Why?
|
| Cataract | 4 | 2010 | 87 | 0.180 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 57 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 684 | 0.180 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 10 | 0.180 |
Why?
|
| Recurrence | 3 | 2023 | 1211 | 0.180 |
Why?
|
| Technology | 1 | 2022 | 35 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2016 | 1021 | 0.180 |
Why?
|
| Medicare | 2 | 2022 | 458 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 463 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 148 | 0.170 |
Why?
|
| Meningeal Neoplasms | 2 | 2012 | 73 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 125 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2025 | 408 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2022 | 217 | 0.170 |
Why?
|
| Everolimus | 1 | 2020 | 36 | 0.170 |
Why?
|
| Cataract Extraction | 2 | 2010 | 32 | 0.160 |
Why?
|
| Methotrexate | 1 | 2021 | 232 | 0.160 |
Why?
|
| Spinal Neoplasms | 2 | 2012 | 131 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2020 | 59 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2018 | 270 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 2 | 2013 | 374 | 0.160 |
Why?
|
| Oximes | 1 | 2019 | 18 | 0.160 |
Why?
|
| Massachusetts | 3 | 2018 | 35 | 0.150 |
Why?
|
| Anterior Eye Segment | 2 | 2010 | 9 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 5 | 2019 | 270 | 0.150 |
Why?
|
| Mesencephalon | 1 | 2000 | 69 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2013 | 15 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2022 | 403 | 0.150 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 1194 | 0.150 |
Why?
|
| Pediatrics | 3 | 2016 | 399 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2018 | 76 | 0.150 |
Why?
|
| Radiation Injuries | 2 | 2018 | 159 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 458 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2013 | 416 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2020 | 135 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 144 | 0.150 |
Why?
|
| Neovascularization, Physiologic | 2 | 2011 | 142 | 0.150 |
Why?
|
| Animals | 21 | 2017 | 28889 | 0.150 |
Why?
|
| Receptor, EphB4 | 2 | 2012 | 23 | 0.150 |
Why?
|
| Carcinoma | 1 | 2002 | 444 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2014 | 102 | 0.140 |
Why?
|
| Mental Disorders | 2 | 2009 | 463 | 0.140 |
Why?
|
| Prospective Studies | 10 | 2022 | 4664 | 0.140 |
Why?
|
| Blood Vessels | 3 | 2007 | 92 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2010 | 747 | 0.140 |
Why?
|
| Proton Therapy | 1 | 2018 | 36 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2018 | 59 | 0.140 |
Why?
|
| Ependymoma | 2 | 2012 | 29 | 0.140 |
Why?
|
| Taxoids | 1 | 2018 | 129 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1176 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 207 | 0.130 |
Why?
|
| Biphenyl Compounds | 1 | 2017 | 62 | 0.130 |
Why?
|
| Brain Stem | 1 | 2018 | 170 | 0.130 |
Why?
|
| Quinazolines | 2 | 2010 | 216 | 0.130 |
Why?
|
| Etoposide | 3 | 2025 | 207 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 484 | 0.130 |
Why?
|
| Neurons | 2 | 2018 | 1653 | 0.130 |
Why?
|
| Postoperative Period | 2 | 2010 | 318 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 468 | 0.130 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2016 | 3 | 0.130 |
Why?
|
| Hospitalization | 1 | 2022 | 943 | 0.130 |
Why?
|
| Antigens, CD34 | 3 | 2013 | 163 | 0.120 |
Why?
|
| Hypertension | 1 | 2022 | 774 | 0.120 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 21 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2017 | 112 | 0.120 |
Why?
|
| Cognition | 2 | 2018 | 635 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7215 | 0.120 |
Why?
|
| Community Mental Health Centers | 1 | 1995 | 6 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2012 | 1753 | 0.120 |
Why?
|
| Frontal Lobe | 1 | 2016 | 131 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 3106 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 170 | 0.120 |
Why?
|
| Pyridines | 1 | 2017 | 319 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 1995 | 31 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 155 | 0.110 |
Why?
|
| Histones | 1 | 2017 | 362 | 0.110 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 22 | 0.110 |
Why?
|
| Lymphocyte Depletion | 2 | 2014 | 101 | 0.110 |
Why?
|
| Tissue Distribution | 3 | 2019 | 297 | 0.110 |
Why?
|
| Activin Receptors, Type I | 1 | 2014 | 13 | 0.110 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 13 | 0.110 |
Why?
|
| Stroke | 2 | 2013 | 1087 | 0.100 |
Why?
|
| Niacinamide | 1 | 2014 | 102 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 235 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1230 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2014 | 2611 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2014 | 126 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 297 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 99 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2014 | 1425 | 0.100 |
Why?
|
| Neurofibromin 1 | 1 | 2013 | 8 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2013 | 10 | 0.100 |
Why?
|
| Mice | 14 | 2014 | 12537 | 0.100 |
Why?
|
| Anaplasia | 2 | 2004 | 5 | 0.100 |
Why?
|
| Disease Progression | 5 | 2014 | 1559 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 1069 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2025 | 292 | 0.100 |
Why?
|
| Candidemia | 1 | 2013 | 1 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 1996 | 447 | 0.100 |
Why?
|
| Ophthalmoscopy | 1 | 2013 | 11 | 0.100 |
Why?
|
| Microsurgery | 2 | 2011 | 99 | 0.100 |
Why?
|
| Eye Infections, Fungal | 1 | 2013 | 13 | 0.100 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2013 | 43 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2013 | 217 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 123 | 0.100 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 24 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 106 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 81 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 62 | 0.100 |
Why?
|
| Vincristine | 2 | 2025 | 101 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 301 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2013 | 226 | 0.090 |
Why?
|
| Adenocarcinoma | 4 | 2012 | 1192 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2013 | 175 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2013 | 446 | 0.090 |
Why?
|
| Paternalism | 1 | 2012 | 24 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 1827 | 0.090 |
Why?
|
| Decision Making | 2 | 2022 | 694 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 341 | 0.090 |
Why?
|
| Prednisone | 2 | 2025 | 252 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 883 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 80 | 0.090 |
Why?
|
| Rare Diseases | 1 | 2012 | 71 | 0.090 |
Why?
|
| Cell Separation | 3 | 2012 | 205 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 750 | 0.090 |
Why?
|
| Prevalence | 2 | 2013 | 1349 | 0.090 |
Why?
|
| Cross-Priming | 1 | 2012 | 54 | 0.090 |
Why?
|
| Drosophila Proteins | 1 | 1996 | 523 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 2042 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2025 | 290 | 0.090 |
Why?
|
| Brachial Artery | 1 | 2011 | 36 | 0.090 |
Why?
|
| Genes, p16 | 1 | 2011 | 10 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 380 | 0.090 |
Why?
|
| Neurosurgical Procedures | 2 | 2012 | 356 | 0.090 |
Why?
|
| Visual Acuity | 2 | 2009 | 209 | 0.090 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 26 | 0.080 |
Why?
|
| Meningioma | 1 | 2011 | 68 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 118 | 0.080 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 69 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1957 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2011 | 136 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 34 | 0.080 |
Why?
|
| Cellular Senescence | 1 | 2011 | 106 | 0.080 |
Why?
|
| Aorta, Abdominal | 1 | 2010 | 60 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 102 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1346 | 0.080 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2009 | 4 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2012 | 315 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 197 | 0.080 |
Why?
|
| Chemokines, CXC | 2 | 2007 | 22 | 0.080 |
Why?
|
| Cell Count | 2 | 2007 | 202 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 345 | 0.080 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 549 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2010 | 99 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2013 | 681 | 0.080 |
Why?
|
| Homeostasis | 1 | 2012 | 467 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 27 | 0.080 |
Why?
|
| Pediatric Nursing | 1 | 2009 | 7 | 0.080 |
Why?
|
| Laser Coagulation | 1 | 2009 | 55 | 0.080 |
Why?
|
| Oncology Nursing | 1 | 2009 | 10 | 0.070 |
Why?
|
| Hyperoxia | 1 | 2009 | 37 | 0.070 |
Why?
|
| Total Quality Management | 1 | 2009 | 34 | 0.070 |
Why?
|
| Age of Onset | 2 | 2020 | 344 | 0.070 |
Why?
|
| Parents | 1 | 2012 | 307 | 0.070 |
Why?
|
| Medical Order Entry Systems | 1 | 2009 | 27 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 116 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 277 | 0.070 |
Why?
|
| Genome, Human | 1 | 2014 | 824 | 0.070 |
Why?
|
| Capillaries | 1 | 2009 | 85 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2007 | 73 | 0.070 |
Why?
|
| Calcinosis | 1 | 2010 | 232 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 395 | 0.070 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 21 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 810 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1267 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2010 | 201 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 350 | 0.070 |
Why?
|
| Fluid Therapy | 1 | 2009 | 67 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 367 | 0.070 |
Why?
|
| Smoking | 1 | 2013 | 649 | 0.070 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 68 | 0.070 |
Why?
|
| Chondroitin | 1 | 2008 | 19 | 0.070 |
Why?
|
| Uveitis, Anterior | 1 | 2008 | 5 | 0.070 |
Why?
|
| Teratoma | 1 | 2008 | 58 | 0.070 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2008 | 11 | 0.070 |
Why?
|
| Foreign-Body Reaction | 1 | 2008 | 11 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 2008 | 19 | 0.070 |
Why?
|
| Social Values | 1 | 2008 | 44 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 341 | 0.070 |
Why?
|
| Photography | 1 | 2008 | 38 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 481 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2011 | 775 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 53 | 0.070 |
Why?
|
| Endothelium, Corneal | 1 | 2007 | 19 | 0.070 |
Why?
|
| Quinolones | 1 | 2007 | 57 | 0.070 |
Why?
|
| Corneal Diseases | 1 | 2007 | 29 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2007 | 95 | 0.070 |
Why?
|
| Regeneration | 1 | 2008 | 161 | 0.070 |
Why?
|
| Patient Safety | 2 | 2019 | 223 | 0.060 |
Why?
|
| Anisotropy | 2 | 2018 | 65 | 0.060 |
Why?
|
| Ovary | 1 | 2008 | 267 | 0.060 |
Why?
|
| Adult Stem Cells | 1 | 2007 | 32 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 226 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1662 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 712 | 0.060 |
Why?
|
| CD146 Antigen | 1 | 2006 | 4 | 0.060 |
Why?
|
| Brain Edema | 1 | 2007 | 61 | 0.060 |
Why?
|
| Poverty | 1 | 2008 | 196 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2012 | 1540 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 816 | 0.060 |
Why?
|
| Optic Disk | 1 | 2006 | 14 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 623 | 0.060 |
Why?
|
| Macula Lutea | 1 | 2006 | 17 | 0.060 |
Why?
|
| Germinoma | 1 | 2006 | 3 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2014 | 3491 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2014 | 365 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2008 | 705 | 0.060 |
Why?
|
| Social Support | 1 | 2008 | 239 | 0.060 |
Why?
|
| Rats | 5 | 2009 | 4154 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 228 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2014 | 2161 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 930 | 0.060 |
Why?
|
| Quantum Dots | 1 | 2005 | 20 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 640 | 0.060 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2005 | 17 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 175 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 1765 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 325 | 0.050 |
Why?
|
| Bone Marrow Purging | 1 | 2004 | 7 | 0.050 |
Why?
|
| Physicians | 1 | 2012 | 706 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2009 | 413 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2020 | 322 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 26 | 0.050 |
Why?
|
| Necrosis | 2 | 2018 | 210 | 0.050 |
Why?
|
| Receptor, trkC | 1 | 2004 | 2 | 0.050 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 250 | 0.050 |
Why?
|
| Lung | 2 | 2009 | 1380 | 0.050 |
Why?
|
| Electroporation | 1 | 2004 | 57 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 451 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2022 | 983 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 1008 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2003 | 353 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 270 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2018 | 297 | 0.050 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 38 | 0.050 |
Why?
|
| Cell Line | 4 | 2007 | 2536 | 0.050 |
Why?
|
| Centrosome | 1 | 2003 | 25 | 0.050 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2002 | 7 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2882 | 0.050 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 13 | 0.050 |
Why?
|
| Zebrafish Proteins | 1 | 2004 | 160 | 0.050 |
Why?
|
| Iris Diseases | 1 | 2002 | 5 | 0.050 |
Why?
|
| Memory | 2 | 2016 | 229 | 0.050 |
Why?
|
| Artifacts | 1 | 2004 | 252 | 0.050 |
Why?
|
| Norethindrone | 1 | 2022 | 13 | 0.050 |
Why?
|
| Progestins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 857 | 0.050 |
Why?
|
| Levonorgestrel | 1 | 2022 | 11 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2022 | 23 | 0.050 |
Why?
|
| Phenotype | 4 | 2011 | 2575 | 0.050 |
Why?
|
| Base Sequence | 4 | 2014 | 2342 | 0.050 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 107 | 0.050 |
Why?
|
| Progesterone | 1 | 2022 | 112 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2009 | 199 | 0.050 |
Why?
|
| China | 1 | 2002 | 264 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 139 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 206 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 60 | 0.040 |
Why?
|
| Chicago | 2 | 2017 | 1505 | 0.040 |
Why?
|
| Cysts | 1 | 2002 | 104 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 109 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 710 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 121 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2001 | 52 | 0.040 |
Why?
|
| Baltimore | 2 | 2013 | 43 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 284 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 127 | 0.040 |
Why?
|
| Craniotomy | 1 | 2001 | 97 | 0.040 |
Why?
|
| Sirolimus | 1 | 2022 | 177 | 0.040 |
Why?
|
| Antibodies | 2 | 2008 | 356 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2001 | 108 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2002 | 139 | 0.040 |
Why?
|
| Diencephalon | 1 | 2000 | 6 | 0.040 |
Why?
|
| Bevacizumab | 3 | 2007 | 275 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 264 | 0.040 |
Why?
|
| RNA, Messenger | 5 | 2010 | 2089 | 0.040 |
Why?
|
| Time Factors | 3 | 2020 | 5561 | 0.040 |
Why?
|
| Linear Models | 2 | 2011 | 438 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2017 | 686 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1805 | 0.040 |
Why?
|
| Palliative Care | 1 | 2001 | 271 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 547 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2014 | 480 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1998 | 8 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 1998 | 42 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 5 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 14 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1791 | 0.030 |
Why?
|
| Cryptosporidiosis | 1 | 1998 | 6 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2018 | 119 | 0.030 |
Why?
|
| Florida | 1 | 2018 | 63 | 0.030 |
Why?
|
| Morbidity | 1 | 2018 | 160 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 1645 | 0.030 |
Why?
|
| Reoperation | 1 | 2001 | 707 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 40 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 72 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 78 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 3040 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 36 | 0.030 |
Why?
|
| Photons | 1 | 2018 | 49 | 0.030 |
Why?
|
| Texas | 1 | 2018 | 131 | 0.030 |
Why?
|
| Behavior | 1 | 2018 | 87 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2012 | 59 | 0.030 |
Why?
|
| Uncertainty | 1 | 2018 | 82 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1998 | 151 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2012 | 182 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2777 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1998 | 96 | 0.030 |
Why?
|
| Hypoxia | 1 | 2022 | 681 | 0.030 |
Why?
|
| White Matter | 1 | 2018 | 96 | 0.030 |
Why?
|
| Helix-Turn-Helix Motifs | 1 | 1996 | 7 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 1996 | 6 | 0.030 |
Why?
|
| Registries | 1 | 2022 | 985 | 0.030 |
Why?
|
| Cetuximab | 1 | 2017 | 119 | 0.030 |
Why?
|
| Chemokine CXCL12 | 2 | 2007 | 38 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 153 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 1996 | 60 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 71 | 0.030 |
Why?
|
| Antineoplastic Protocols | 1 | 2016 | 9 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 188 | 0.030 |
Why?
|
| Codon | 1 | 1996 | 120 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 1996 | 124 | 0.030 |
Why?
|
| Lomustine | 1 | 2016 | 24 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 202 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 282 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 910 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2011 | 1046 | 0.030 |
Why?
|
| Rehabilitation, Vocational | 1 | 1995 | 4 | 0.030 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1995 | 16 | 0.030 |
Why?
|
| Case Management | 1 | 1995 | 29 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 198 | 0.030 |
Why?
|
| Hostility | 1 | 1995 | 25 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1030 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 175 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1998 | 400 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3237 | 0.030 |
Why?
|
| Intestines | 1 | 1998 | 432 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1208 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1816 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 1006 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1996 | 477 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 713 | 0.030 |
Why?
|
| Cyclins | 1 | 1994 | 80 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2014 | 44 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1996 | 618 | 0.030 |
Why?
|
| Personality Disorders | 1 | 1995 | 145 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 112 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 223 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 900 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 147 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 132 | 0.020 |
Why?
|
| Candida | 1 | 2013 | 20 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 191 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2014 | 188 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2012 | 11 | 0.020 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 292 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2013 | 72 | 0.020 |
Why?
|
| Apoptosis | 2 | 2000 | 1756 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 61 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2012 | 53 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 132 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1996 | 677 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 128 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1965 | 0.020 |
Why?
|
| Ethical Analysis | 1 | 2012 | 23 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 306 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 279 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 579 | 0.020 |
Why?
|
| Drosophila | 1 | 1996 | 539 | 0.020 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 94 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 212 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 39 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1192 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 52 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 45 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 599 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 299 | 0.020 |
Why?
|
| Elasticity | 1 | 2011 | 104 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 96 | 0.020 |
Why?
|
| Research | 1 | 2012 | 265 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2011 | 70 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 23 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 83 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 38 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 298 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 96 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 252 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 816 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2013 | 244 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 528 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2929 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 72 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2003 | 257 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 224 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 85 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 556 | 0.020 |
Why?
|
| Mitosis | 1 | 2010 | 152 | 0.020 |
Why?
|
| Clodronic Acid | 1 | 2010 | 9 | 0.020 |
Why?
|
| Etanercept | 1 | 2010 | 33 | 0.020 |
Why?
|
| Research Report | 1 | 2010 | 43 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 90 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 692 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 99 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 357 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 111 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 760 | 0.020 |
Why?
|
| Epigenomics | 1 | 2010 | 109 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 648 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 2773 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 515 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 1080 | 0.020 |
Why?
|
| Nursing Audit | 1 | 2009 | 2 | 0.020 |
Why?
|
| Nursing Evaluation Research | 1 | 2009 | 3 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 149 | 0.020 |
Why?
|
| Medication Systems, Hospital | 1 | 2009 | 7 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2009 | 38 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 21 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 703 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 176 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2009 | 17 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 24 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 1319 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 55 | 0.020 |
Why?
|
| Safety Management | 1 | 2009 | 58 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 378 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 700 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2008 | 8 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2008 | 58 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 383 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 311 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 162 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 897 | 0.020 |
Why?
|
| Program Development | 1 | 2009 | 136 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 1023 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1714 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 2008 | 8 | 0.020 |
Why?
|
| Neuroectodermal Tumors | 1 | 2007 | 2 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 2008 | 43 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 128 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1310 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 138 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1156 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 213 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 314 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 323 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2009 | 144 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 121 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2010 | 267 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 465 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 542 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 450 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 2090 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1561 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1267 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 86 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 3581 | 0.020 |
Why?
|
| Fluorescence | 1 | 2006 | 104 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 2006 | 83 | 0.010 |
Why?
|
| Intraocular Pressure | 1 | 2006 | 63 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1878 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1087 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 231 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2534 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 173 | 0.010 |
Why?
|
| Remission Induction | 1 | 2007 | 750 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 1957 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1011 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2009 | 532 | 0.010 |
Why?
|
| Monocytes | 1 | 2006 | 220 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 372 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2004 | 16 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 69 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 71 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 80 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 549 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 215 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 2480 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 32 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2004 | 131 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 255 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2006 | 513 | 0.010 |
Why?
|
| Codon, Initiator | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 227 | 0.010 |
Why?
|
| Mesoderm | 1 | 2003 | 122 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 98 | 0.010 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 47 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2494 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 548 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 266 | 0.010 |
Why?
|
| Microtubules | 1 | 2003 | 134 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 326 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 394 | 0.010 |
Why?
|
| Glaucoma | 1 | 2002 | 36 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 241 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1615 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2003 | 200 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 740 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1079 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2039 | 0.010 |
Why?
|
| Drainage | 1 | 2002 | 172 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 816 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 495 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 323 | 0.010 |
Why?
|
| Rosette Formation | 1 | 2000 | 29 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1124 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 1319 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 1167 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 463 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 996 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1560 | 0.010 |
Why?
|
| Neutrophils | 1 | 2000 | 328 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 52 | 0.010 |
Why?
|
| Thalamus | 1 | 2000 | 135 | 0.010 |
Why?
|
| Cryptosporidium parvum | 1 | 1998 | 4 | 0.010 |
Why?
|
| Defensins | 1 | 1998 | 5 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 158 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 385 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 312 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 1730 | 0.010 |
Why?
|
| Zinc | 1 | 1994 | 101 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 995 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2386 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 701 | 0.010 |
Why?
|
| Transfection | 1 | 1994 | 908 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 3155 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 2061 | 0.000 |
Why?
|